ACXEL Tech is a technology company.
ACXEL Tech is a technology company.
ACXEL Tech has raised $24.0M across 2 funding rounds.
ACXEL Tech has raised $24.0M in total across 2 funding rounds.
ACXEL Tech (also referred to as Guangdong Acxel Micro & Nano Tech Co., Ltd. or ACXEL TECH LTD) is a technology company specializing in microfluidic platforms for life sciences, leveraging semiconductor technology to enable precise control of single-cell droplets on AMPixel chips.[1][5][6] It builds tools for high-throughput single-cell workflows, including sample preparation for multi-omics and proteomics, as well as antibody discovery via phage display and single B cell screening, serving life science researchers and labs tackling cellular heterogeneity.[1][5] The company solves inefficiencies in traditional lab processes by digitizing and parallelizing droplet control, bringing workflows onto microfluidic chips to boost productivity and meet unmet research needs.[1]
With a focus on high-speed, programmable liquid droplet transport, ACXEL Tech demonstrates growth momentum through participation in major events like the BIO International Convention and establishment as a UK-registered entity (ACXEL TECH LTD, company number 09838006), indicating international expansion from its base in Foshan, Guangdong, China.[1][6]
ACXEL Tech emerged from expertise in semiconductor and microfluidics, founded in Foshan, Guangdong, China, with a UK incorporation as ACXEL TECH LTD in 2015 (exact month not specified in records).[1][6] The core idea stemmed from applying semiconductor precision to life sciences, developing the AMPixel chip for independent droplet control at the single-cell level to streamline complex workflows previously limited by manual or low-throughput methods.[1][5] Early traction likely built on this innovation, as evidenced by their booth presence at the BIO International Convention, showcasing products like single-cell multi-omics tools and antibody screening platforms, marking a pivotal step in commercializing digital lab solutions.[1]
ACXEL Tech rides the single-cell analysis trend, fueled by booming demand in precision medicine, immunology, and drug discovery where understanding cellular heterogeneity is critical.[1] Timing aligns with advances in multi-omics (genomics, proteomics) and AI-driven biology, where microfluidic digitization accelerates data generation amid a global push for faster antibody development post-pandemic.[1][5] Market forces like rising biotech R&D investments (e.g., via events like BIO Convention) and semiconductor crossovers into biotech favor its model, reducing lab costs and time.[1] It influences the ecosystem by providing "critical enabling technologies," empowering researchers to scale experiments and potentially speeding innovations in therapeutics and diagnostics.[1]
ACXEL Tech is poised to expand its AMPixel platform into more integrated lab-on-chip solutions, capitalizing on AI-bio convergence and growing single-cell markets projected to surge with personalized medicine demands.[1][5] Trends like automated workflows and high-throughput screening will shape its path, potentially through partnerships with pharma giants or further global scaling beyond China and UK filings.[6] Its influence may evolve from niche enabler to standard tool in digital life sciences, amplifying biotech productivity—if it sustains momentum in competitive microfluidics. This positions ACXEL Tech as a key player digitizing the lab of tomorrow, directly advancing the high-level mission of semiconductor-enabled life science innovation.[1]
ACXEL Tech has raised $24.0M in total across 2 funding rounds.
ACXEL Tech's investors include Qiming Venture Partners.
ACXEL Tech has raised $24.0M across 2 funding rounds. Most recently, it raised $14.0M Series A in December 2023.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Dec 1, 2023 | $14.0M Series A | Qiming Venture Partners | |
| Mar 1, 2022 | $10.0M Seed | Qiming Venture Partners |